Post-heart transplantation lymphoproliferative diseases (PTLDs) and the diagnostic role of [18f] FDG-PET/CT.
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Female
Fluorodeoxyglucose F18
Heart Transplantation
/ adverse effects
Hodgkin Disease
/ diagnostic imaging
Humans
Hyperplasia
/ diagnostic imaging
Immunocompromised Host
Lymphoma, Non-Hodgkin
/ diagnostic imaging
Lymphoproliferative Disorders
/ diagnostic imaging
Male
Middle Aged
Positron Emission Tomography Computed Tomography
/ methods
Postoperative Complications
/ diagnostic imaging
Radiopharmaceuticals
Journal
Minerva medica
ISSN: 1827-1669
Titre abrégé: Minerva Med
Pays: Italy
ID NLM: 0400732
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
pubmed:
15
5
2020
medline:
28
5
2021
entrez:
15
5
2020
Statut:
ppublish
Résumé
The incidence of cancer is higher in transplant patients than in the normal population, mostly due to the assumption of immunosuppressants able to reduce the possibility of rejection. In addition, immunocompromised patients have a greater susceptibility to EBV, HPV and HIV, infectious agents that by themselves may favor the onset of malignancies. Post-transplant lymphoproliferative diseases (PLDs) are among the most frequent neoplasms in transplant patients which like other aggressive neoplasms may be identified by the [18f] fluoro-D-deoxyglucose positron emission tomography/computed tomography (FDG-PET/CT). We evaluated the clinical use of FDG-PET/CT in detecting PTLDs and other neoplasms performed at the lowest clinical or laboratory suspicion of malignancy in 127 consecutive subjects who underwent heart transplantation. A SUV>4 more confirmed the suspect of malignancy and induced us to further investigations. Of the 127 transplant subjects who underwent FDG-PET/CT, 64 showed a SUV value >4. Of these 64, 8 had PTLDs, 49 other neoplasms (urinary tract tumors, thyroid cancer, HPV cancer related, Kaposi' sarcoma and EBV related head and neck neoplasms) and 7 patients with chronic non-neoplastic inflammatory diseases. In the present study, FDG-PET/CT examination was of great use for an early identification and for an early treatment of PTLDs and other neoplasms.
Sections du résumé
BACKGROUND
BACKGROUND
The incidence of cancer is higher in transplant patients than in the normal population, mostly due to the assumption of immunosuppressants able to reduce the possibility of rejection. In addition, immunocompromised patients have a greater susceptibility to EBV, HPV and HIV, infectious agents that by themselves may favor the onset of malignancies. Post-transplant lymphoproliferative diseases (PLDs) are among the most frequent neoplasms in transplant patients which like other aggressive neoplasms may be identified by the [18f] fluoro-D-deoxyglucose positron emission tomography/computed tomography (FDG-PET/CT).
METHODS
METHODS
We evaluated the clinical use of FDG-PET/CT in detecting PTLDs and other neoplasms performed at the lowest clinical or laboratory suspicion of malignancy in 127 consecutive subjects who underwent heart transplantation.
RESULTS
RESULTS
A SUV>4 more confirmed the suspect of malignancy and induced us to further investigations. Of the 127 transplant subjects who underwent FDG-PET/CT, 64 showed a SUV value >4. Of these 64, 8 had PTLDs, 49 other neoplasms (urinary tract tumors, thyroid cancer, HPV cancer related, Kaposi' sarcoma and EBV related head and neck neoplasms) and 7 patients with chronic non-neoplastic inflammatory diseases.
CONCLUSIONS
CONCLUSIONS
In the present study, FDG-PET/CT examination was of great use for an early identification and for an early treatment of PTLDs and other neoplasms.
Identifiants
pubmed: 32407047
pii: S0026-4806.20.06607-0
doi: 10.23736/S0026-4806.20.06607-0
doi:
Substances chimiques
Radiopharmaceuticals
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM